PRF1 and non-small cell lung carcinoma: Genes that were positively associated with disease control (n=3) in the NSCLC subgroup (total n=9) represented multiple immune-related functions, including some that have been associated with improved outcome from immune checkpoint inhibitor therapy, such as CD8A, GZMB, PRF1, (consistent with the immunohistochemistry results), CXCL9, CXCL10, CXCR6, GZMA, and IDO1 (Figure 2B) (27, 31–33).